First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity

<strong>Background:</strong> Bromodomain and extraterminal motif (BET) protein inhibition is a promising cancer treatment strategy, notably for targeting MYC- or BRD4-driven diseases. A first-in-human study investigated the safety, pharmacokinetics, maximum tolerated dose and recommended...

Full description

Bibliographic Details
Main Authors:	Postel-Vinay, S, Herbschleb, K, Massard, C, Woodcock, V, Soria, J-C, Walter, AO, Ewerton, F, Poelman, M, Benson, N, Ocker, M, Wilkinson, G, Middleton, MR
Format:	Journal article
Published:	Elsevier 2019

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity

Similar Items